Joshua Friedman
Corporate Officer/Principal bei SPYRE THERAPEUTICS, INC.
Profil
Joshua Friedman is currently the Senior Vice President-Clinical Development at Spyre Therapeutics, Inc. Prior to his current position, he worked as the Senior Director-Clinical Research at Alnylam Pharmaceuticals, Inc. from 2019 to 2022.
He also served as the Vice President & Head-Translational Science at Spark Therapeutics, Inc. from 2022 to 2023.
Dr. Friedman completed his undergraduate degree at Harvard University and obtained a doctorate from the University of Pennsylvania.
Aktive Positionen von Joshua Friedman
| Unternehmen | Position | Beginn |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Corporate Officer/Principal | 27.11.2023 |
Ehemalige bekannte Positionen von Joshua Friedman
| Unternehmen | Position | Ende |
|---|---|---|
| SPARK THERAPEUTICS, INC. | Corporate Officer/Principal | 01.07.2023 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2022 |
Ausbildung von Joshua Friedman
| Harvard University | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
